- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction
This study looks at a new drug, vericiguat, for people with long-term heart failure where the heart struggles to pump blood. It compares vericiguat with a dummy pill to see if it can prevent heart-related deaths or hospital stays, and if it's safe.
For: Chronic Heart Failure With Reduced Ejection FractionSweden · Spain · Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Single-arm, Open-label Extension of the Vericiguat VALOR Study in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR EXT)
This study looks at a medicine called Vericiguat for children with a type of heart failure. It checks how safe the medicine is and if it causes any unwanted effects. This is a follow-up study for those already taking part.
For: Heart Failure due to Systemic Left Ventricular Systolic DysfunctionItaly · Portugal · Sweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A parallel-group treatment, phase 2a, double-blind, placebo-controlled 2-arm study to show improvement of physical function in SF-36 (SF-36-PF) in participants treated with Vericiguat compared to placebo tablets participants with post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of ME/CFS criteria - VERI-LONG
This study looks at a new medicine called Vericiguat for people with ongoing symptoms after COVID-19. It aims to see if Vericiguat can improve physical activity and reduce fatigue compared to a dummy pill.
For: Post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of myalgic encephalomyelitis/chronic fatique syndrome (ME/CFS) criteriaGermany